Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRTA 
Prothena Corporation plc (PRTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PRTA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15
1 Year Target Price $15
| 5 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.34% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 441.41M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 10 | Beta -0.03 | 52 Weeks Range 4.32 - 22.83 | Updated Date 08/29/2025 |
52 Weeks Range 4.32 - 22.83 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When - | Estimate -1.22 | Actual -2.34 |
Profitability
Profit Margin - | Operating Margin (TTM) -1176.63% |
Management Effectiveness
Return on Assets (TTM) -29.8% | Return on Equity (TTM) -66.85% |
Valuation
Trailing PE - | Forward PE 64.1 | Enterprise Value 81905051 | Price to Sales(TTM) 42.69 |
Enterprise Value 81905051 | Price to Sales(TTM) 42.69 | ||
Enterprise Value to Revenue 7.92 | Enterprise Value to EBITDA -3.58 | Shares Outstanding 53830000 | Shares Floating 40091494 |
Shares Outstanding 53830000 | Shares Floating 40091494 | ||
Percent Insiders 18.66 | Percent Institutions 79.74 |
Upturn AI SWOT
Prothena Corporation plc
Company Overview
History and Background
Prothena Corporation plc, founded in 2012, focuses on developing novel therapeutics for neurodegenerative diseases. It evolved from Elan Corporation's research programs.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Prothena focuses on developing therapies targeting misfolded proteins implicated in diseases like Alzheimer's, Parkinson's, and ATTR amyloidosis.
- Antibody Development: The company specializes in creating antibodies that can target and clear these problematic proteins.
Leadership and Structure
Gene Kinney is the President and CEO. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- PRX012 (Alzheimer's Disease): PRX012 is an anti-Au03b2 antibody being developed for the treatment of Alzheimer's disease. Competitors include Biogen (LEQEMBI), Eli Lilly (donanemab), and Roche (gantenerumab). Market share is currently emerging.
- Birtamimab (ATTR Amyloidosis): Birtamimab is designed to neutralize soluble transthyretin aggregates in ATTR amyloidosis. Competitors include Alnylam Pharmaceuticals (ONPATTRO, AMVUTTRA) and Ionis Pharmaceuticals (Wainua). Phase 3 failure led to program halt.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on neurodegenerative diseases is characterized by high unmet need, significant investment in research and development, and regulatory hurdles.
Positioning
Prothena is a clinical-stage biotechnology company positioned to address significant unmet needs in neurodegenerative diseases. Its competitive advantage lies in its antibody engineering platform and expertise in targeting protein misfolding.
Total Addressable Market (TAM)
The total addressable market for Alzheimer's and Parkinson's therapeutics is estimated to be in the tens of billions of dollars. Prothena is positioned to capture a portion of this TAM with its innovative therapies, contingent on clinical success and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary antibody technology platform
- Strong scientific expertise in neurodegenerative diseases
- Experienced management team
- Focused pipeline of therapeutic candidates
Weaknesses
- Dependence on clinical trial outcomes
- High cash burn rate
- Relatively small company size
- Past clinical trial failures (Birtamimab)
Opportunities
- Partnerships with larger pharmaceutical companies
- Advancements in diagnostic tools for early disease detection
- Expansion into new disease areas
- Regulatory approval of innovative therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ALNY
- IONS
Competitive Landscape
Prothena faces significant competition from larger pharmaceutical companies with more established resources. Prothena's advantage lies in its specialized focus and innovative antibody platform, but it must navigate the risks associated with clinical development and regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily based on R&D progress and securing funding. It is not directly reflected in revenue, which is typical for a clinical-stage biotech.
Future Projections: Future projections depend heavily on the success of ongoing clinical trials, particularly PRX012 in Alzheimer's disease. Analyst estimates vary widely depending on probability of clinical success.
Recent Initiatives: Recent initiatives include advancing PRX012 in clinical trials and exploring new therapeutic targets in neurodegenerative diseases.
Summary
Prothena is a clinical-stage biotechnology company focused on neurodegenerative diseases with a promising antibody technology platform. The company's future hinges on the success of its lead candidate, PRX012, and faces challenges due to its reliance on clinical trial outcomes and competition from larger companies. Clinical trial failures and regulatory hurdles pose significant threats. Successful development and commercialization could provide significant returns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Prothena Corporation plc SEC Filings (10-K, 10-Q), Company Website, Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual due diligence and consultation with a financial professional. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prothena Corporation plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2012-12-21 | President, CEO & Director Dr. Gene G. Kinney Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.prothena.com |
Full time employees 163 | Website https://www.prothena.com | ||
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.